GlassScriptPhysician profile
Richard M Baley
NPI 1184693327
$6,770.43
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,375 · 2020: $921 · 2021: $1,074 · 2022: $1,341 · 2023: $1,639 · 2024: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,058.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,465.81 | 2019-2024 | Jardiance, Spiriva Respimat, Tradjenta |
| Amgen INC. | $822.89 | 2019-2024 | Repatha, Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $717.11 | 2019-2024 | Spravato, Xarelto |
| Novo Nordisk INC | $651.12 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $650.81 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Amarin Pharma, INC. | $416.49 | 2019-2022 | |
| Pfizer INC. | $311.47 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $278.73 | 2023-2024 | |
| Lilly USA, LLC | $218.05 | 2020-2024 | Mounjaro, Jardiance, Emgality |
| Sanofi-Aventis U.S. LLC | $186.27 | 2019-2023 | |
| Abbvie INC. | $155.89 | 2019-2024 | Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $145.53 | 2021-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $115.38 | 2019-2022 | |
| Exact Sciences Corporation | $95.09 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $71.64 | 2019-2023 | Shingrix, Arexvy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $71.28 | 2019-2022 | |
| Abbott Laboratories | $65.99 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $51.97 | 2019 | |
| Genentech USA, INC. | $45.63 | 2019 | |
| Jazz Pharmaceuticals INC. | $45.02 | 2019 | |
| Corium, LLC | $43.50 | 2023 | Adlarity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.87 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.09 | 2022 | |
| Boston Scientific Corporation | $22.42 | 2019 | |
| Ibsa Pharma INC. | $18.75 | 2021 | |
| Sanofi Pasteur INC. | $15.14 | 2019 | |
| Corcept Therapeutics | $14.73 | 2019 | |
| Allergan, INC. | $13.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Baley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.